Background: Hypertension control is often inadequate in HIV patients. In a contemporary, nationwide cohort of Italian HIV-infected adults, we assessed time trends in hypertension prevalence, awareness, treatment, and control. We also evaluated predictors of cardiovascular events and of new-onset hypertension. Methods: Multicenter prospective cohort study, sampling 961 consecutive HIV patients (71% men, mean age 46 ± 9 years, 30% hypertensive) examined in 2010-2014 and after a median follow-up of 3.4 years. Results: Among hypertensive patients, hypertension awareness (63% at baseline and 92% at follow-up), treatment (54 vs. 79%), and control (35 vs. 59%) all improved during follow-up. The incidence of new-onset hypertension was 50.1/1000 person-years (95% confidence interval, 41.2-60.3). Multivariable-adjusted predictors of hypertension were age, BMI, estimated cardiovascular risk, blood pressure, and advanced HIV clinical stage. In total, 35 new cardiovascular events were reported during follow-up (11.1/1000 person-years). In a multivariate model, baseline cardiovascular risk and hypertensive status predicted incident cardiovascular events, whereas a higher CD4 cell count had a protective role. In treated hypertensive patients, the use of integrase strand transfer inhibitors at follow-up was associated with a lower SBP (average yearly change,-3.8 ± 1.6 vs.-0.9 ± 0.5 mmHg in integrase strand transfer inhibitor users vs. nonusers, respectively, P = 0.02). Conclusion: Hypertension awareness, treatment, and control rates all improved in adult Italian HIV patients over the last few years, although hypertension remains highly prevalent (41%) in middle-aged HIV patients, and significantly impacts cardiovascular morbidity. Traditional risk factors and advanced HIV disease predict new-onset hypertension, whereas CD4 cell count favorably affects future cardiovascular events.

Time trend in hypertension prevalence, awareness, treatment, and control in a contemporary cohort of HIV-infected patients : The HIV and Hypertension Study / G.V. De Socio, E. Ricci, P. Maggi, G. Parruti, B.M. Celesia, G. Orofino, G. Madeddu, C. Martinelli, B. Menzaghi, L. Taramasso, P. Bonfanti, G. Pucci, G. Schillaci. - In: JOURNAL OF HYPERTENSION. - ISSN 0263-6352. - 35:2(2017 Feb), pp. 409-416. [10.1097/HJH.0000000000001150]

Time trend in hypertension prevalence, awareness, treatment, and control in a contemporary cohort of HIV-infected patients : The HIV and Hypertension Study

L. Taramasso;
2017

Abstract

Background: Hypertension control is often inadequate in HIV patients. In a contemporary, nationwide cohort of Italian HIV-infected adults, we assessed time trends in hypertension prevalence, awareness, treatment, and control. We also evaluated predictors of cardiovascular events and of new-onset hypertension. Methods: Multicenter prospective cohort study, sampling 961 consecutive HIV patients (71% men, mean age 46 ± 9 years, 30% hypertensive) examined in 2010-2014 and after a median follow-up of 3.4 years. Results: Among hypertensive patients, hypertension awareness (63% at baseline and 92% at follow-up), treatment (54 vs. 79%), and control (35 vs. 59%) all improved during follow-up. The incidence of new-onset hypertension was 50.1/1000 person-years (95% confidence interval, 41.2-60.3). Multivariable-adjusted predictors of hypertension were age, BMI, estimated cardiovascular risk, blood pressure, and advanced HIV clinical stage. In total, 35 new cardiovascular events were reported during follow-up (11.1/1000 person-years). In a multivariate model, baseline cardiovascular risk and hypertensive status predicted incident cardiovascular events, whereas a higher CD4 cell count had a protective role. In treated hypertensive patients, the use of integrase strand transfer inhibitors at follow-up was associated with a lower SBP (average yearly change,-3.8 ± 1.6 vs.-0.9 ± 0.5 mmHg in integrase strand transfer inhibitor users vs. nonusers, respectively, P = 0.02). Conclusion: Hypertension awareness, treatment, and control rates all improved in adult Italian HIV patients over the last few years, although hypertension remains highly prevalent (41%) in middle-aged HIV patients, and significantly impacts cardiovascular morbidity. Traditional risk factors and advanced HIV disease predict new-onset hypertension, whereas CD4 cell count favorably affects future cardiovascular events.
Antiretroviral therapy; Blood Pressure; Cardiovascular disease; HIV; Hypertension; Integrase inhibitors; New-onset hypertension; Adult; Age Factors; Blood Pressure; Body Mass Index; CD4 Lymphocyte Count; Cardiovascular Diseases; Female; Follow-Up Studies; HIV Infections; Humans; Hypertension; Incidence; Integrase Inhibitors; Italy; Male; Middle Aged; Prevalence; Prospective Studies; Risk Factors; Health Knowledge; Attitudes; Practice
Settore MED/17 - Malattie Infettive
feb-2017
Article (author)
File in questo prodotto:
File Dimensione Formato  
De socio J HYP (1).pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 276.46 kB
Formato Adobe PDF
276.46 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Time_trend_in_hypertension_prevalence,_awareness,.29.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 324.41 kB
Formato Adobe PDF
324.41 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/708294
Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 21
  • ???jsp.display-item.citation.isi??? 22
social impact